ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
Korean Journal of Clinical Oncology
◽
10.14216/kjco.18019
◽
2018
◽
Vol 14
(2)
◽
pp. 108-115
Author(s):
Ashraf Mahmoud El-Enbaby
◽
Nadia Ahmed Abd El Moneim
◽
Gehan Abd El atti Khedr
◽
Yasmine Mohamed Nagy Elwany
Keyword(s):
Breast Cancer
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Positive Breast Cancer
Download Full-text
Related Documents
Cited By
References
Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718043513.793482079
◽
2013
◽
Author(s):
Ana Maria Gonzalez-Angulo
Keyword(s):
Breast Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Her2 Positive
◽
Open Label
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Randomised Controlled
◽
Positive Breast Cancer
Download Full-text
Adjuvant Trastuzumab in HER2-Positive Breast Cancer: Observational Monocentric Study of 84 Cases
Annals of Oncology
◽
10.1093/annonc/mdt079.3
◽
2013
◽
Vol 24
◽
pp. iii16
Author(s):
M. Aitelhaj
◽
S. Lkhoyaali
◽
G. Rais
◽
A. Mohtaram
◽
S. Boutayeb
◽
...
Keyword(s):
Breast Cancer
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Positive Breast Cancer
Download Full-text
Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
Medical Molecular Morphology
◽
10.1007/s00795-018-0208-9
◽
2018
◽
Vol 52
(2)
◽
pp. 106-113
Author(s):
Naoki Kanomata
◽
Junichi Kurebayashi
◽
Takuya Moriya
Keyword(s):
Breast Cancer
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Positive Breast Cancer
Download Full-text
Abstract PS10-58: Cost effectiveness of routine cardiac imaging during adjuvant trastuzumab in HER2-positive breast cancer
10.1158/1538-7445.sabcs20-ps10-58
◽
2021
◽
Author(s):
Vineeth Tatineni
◽
Daniel Redle
◽
Daljeet Singh
◽
Arifa Abid
◽
Sameer Mahesh
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Cardiac Imaging
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Positive Breast Cancer
Download Full-text
226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study
Annals of Oncology
◽
10.1016/j.annonc.2020.08.347
◽
2020
◽
Vol 31
◽
pp. S331
Author(s):
C. Molinelli
◽
L. Del Mastro
◽
S. Giraudi
◽
A. Ballestrero
◽
F. Carli
◽
...
Keyword(s):
Breast Cancer
◽
Observational Study
◽
Cancer Patients
◽
Breast Cancer Patients
◽
Cardiac Safety
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Positive Breast Cancer
Download Full-text
Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
PharmacoEconomics
◽
10.1007/s40273-018-0634-5
◽
2018
◽
Vol 36
(4)
◽
pp. 505-505
Author(s):
Amir Ansaripour
◽
Carin A. Uyl-de Groot
◽
W. Ken Redekop
Keyword(s):
Breast Cancer
◽
Cost Effectiveness
◽
Scenario Analysis
◽
Treatment Strategy
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Trastuzumab Therapy
◽
Optimal Treatment Strategy
◽
Positive Breast Cancer
Download Full-text
Abstract P4-12-20: Clinical outcomes of patients with recurrent HER2-positive breast cancer after exposure to adjuvant trastuzumab
10.1158/0008-5472.sabcs13-p4-12-20
◽
2013
◽
Author(s):
DN Mullins
◽
M Abdel-Rasoul
◽
J Querry
◽
D Akuma
◽
A Feng
◽
...
Keyword(s):
Breast Cancer
◽
Clinical Outcomes
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Positive Breast Cancer
Download Full-text
Abstract P1-08-06: Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial
10.1158/0008-5472.sabcs13-p1-08-06
◽
2013
◽
Author(s):
RM Wirtz
◽
M Leinonen
◽
P Bono
◽
J Isola
◽
P-L Kellokumpu-Lehtinen
◽
...
Keyword(s):
Breast Cancer
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Mrna Content
◽
Positive Breast Cancer
Download Full-text
Abstract 5295: Impact of a multi-gene expression profile in predicting adjuvant trastuzumab outcome in HER2-positive breast cancer
10.1158/1538-7445.am2020-5295
◽
2020
◽
Author(s):
Sara Ravaioli
◽
Roberta Maltoni
◽
Francesca Pirini
◽
Michela Palleschi
◽
William Balzi
◽
...
Keyword(s):
Breast Cancer
◽
Gene Expression
◽
Gene Expression Profile
◽
Expression Profile
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Positive Breast Cancer
Download Full-text
Abstract P5-10-18: The chromosomal genomic landscape and targetable co-amplified genes in HER2 positive breast cancer patients who relapsed on an adjuvant trastuzumab chemotherapy trial
10.1158/1538-7445.sabcs14-p5-10-18
◽
2015
◽
Author(s):
Shelly Gunn
◽
Chris McCaskill
◽
Linda Daley
◽
Agnes Puskas
◽
Lina Asmar
◽
...
Keyword(s):
Breast Cancer
◽
Cancer Patients
◽
Breast Cancer Patients
◽
Her2 Positive
◽
Adjuvant Trastuzumab
◽
Her2 Positive Breast Cancer
◽
Genomic Landscape
◽
Positive Breast Cancer
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close